DK0411668T4 - Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser - Google Patents

Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser

Info

Publication number: DK0411668T4
Authority: DK; Denmark
Prior art keywords: treatment; mental disorders; cholecystokinin antagonists; central; central cholecystokinin
Prior art date: 1989-08-04

Application number

DK90114993T

Other languages

English (en)

Other versions

DK0411668T3 (da

Inventor

David Christopher Horwell

John Hughes

Geoff Neil Woodruff

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-04

Filing date

1990-08-03

Publication date

1999-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27012795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0411668(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-08-03 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

1995-03-27 Application granted granted Critical

1995-03-27 Publication of DK0411668T3 publication Critical patent/DK0411668T3/da

1999-08-09 Publication of DK0411668T4 publication Critical patent/DK0411668T4/da

Links

102100025841 Cholecystokinin Human genes 0.000 title 1
101800001982 Cholecystokinin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
229940107137 cholecystokinin Drugs 0.000 title 1
208000020016 psychiatric disease Diseases 0.000 title 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title 1
239000002249 anxiolytic agent Substances 0.000 abstract 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
230000000049 anti-anxiety effect Effects 0.000 abstract 1
230000000561 anti-psychotic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
229960003920 cocaine Drugs 0.000 abstract 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
229960003529 diazepam Drugs 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
229960002715 nicotine Drugs 0.000 abstract 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK90114993T 1989-08-04 1990-08-03 Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser DK0411668T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38966589A	1989-08-04	1989-08-04
US42189689A	1989-10-16	1989-10-16

Publications (2)

Publication Number	Publication Date
DK0411668T3 DK0411668T3 (da)	1995-03-27
DK0411668T4 true DK0411668T4 (da)	1999-08-09

Family

ID=27012795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90114993T DK0411668T4 (da)	1989-08-04	1990-08-03	Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser

Country Status (9)

Country	Link
US (1)	US5550126A (da)
EP (2)	EP0727215A3 (da)
JP (1)	JPH0374328A (da)
AT (1)	ATE119040T1 (da)
CY (1)	CY1983A (da)
DE (1)	DE69017302T3 (da)
DK (1)	DK0411668T4 (da)
HK (1)	HK8197A (da)
LV (1)	LV11431B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0411668T4 (da) *	1989-08-04	1999-08-09	Merck Sharp & Dohme	Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
US5324726A (en) *	1989-12-18	1994-06-28	Merck & Co., Inc.	Benzodiazepine analogs
US5399565A (en) *	1990-07-17	1995-03-21	Eli Lilly And Company	Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5206238A (en) *	1990-11-13	1993-04-27	Merck & Co., Inc.	Cholecystokinin antagonists
US5220017A (en) *	1991-04-10	1993-06-15	Merck & Co., Inc.	Cholecystokinin antagonists
US5218115A (en) *	1991-04-10	1993-06-08	Merck & Co., Inc.	Cholecystokinin antagonists
US5220018A (en) *	1991-04-10	1993-06-15	Merck & Co., Inc.	Cholecystokinin antagonists
US5218114A (en) *	1991-04-10	1993-06-08	Merck & Co., Inc.	Cholecystokinin antagonists
US5185331A (en) *	1991-05-14	1993-02-09	Merck & Co., Inc.	Triazolobenzodiazepines
US5206237A (en) *	1991-05-14	1993-04-27	Merck & Co., Inc.	Benzodiazepine analogs
EP0518484A3 (en) *	1991-05-14	1993-03-17	Merck & Co. Inc.	1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders
US5210082A (en) *	1991-05-16	1993-05-11	Merck & Co., Inc.	2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
WO1992021348A1 (en) *	1991-06-03	1992-12-10	Merck Sharp & Dohme Limited	Pharmaceutical formulations of a benzodiazepine
US5177071A (en) *	1991-06-17	1993-01-05	Merck & Co., Inc.	1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
US5153191A (en) *	1991-08-20	1992-10-06	Warner-Lambert Company	Cholecystokinin antagonists useful for treating depression
WO1993012791A1 (en) *	1991-12-20	1993-07-08	Merck Sharp & Dohme Limited	Central cholecystokinin antagonists having pharmaceutical activity
IT1263116B (it) *	1992-04-09	1996-07-30	Rotta Research Lab	Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
DE69317499T2 (de) *	1992-04-22	1998-07-09	Copal Co Ltd	Absolute kodiereinrichtung
US5360802A (en) *	1992-05-11	1994-11-01	Merck Sharpe & Dohme Ltd.	Benzodiazepine derivatives, compositions containing them and their use in therapy
US5378838A (en) *	1993-01-13	1995-01-03	Merck & Co., Inc.	Benzodiazepine cholecystokinin antagonists
US5852010A (en) *	1996-04-03	1998-12-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1998000406A1 (en) *	1996-07-02	1998-01-08	Merck & Co., Inc.	Method for the treatment of preterm labor
US5929071A (en) *	1996-07-02	1999-07-27	Merck & Co., Inc.	Method for the treatment of preterm labor
US6194459B1 (en)	1997-08-19	2001-02-27	Warner-Lambert Company	Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
NZ525513A (en)	1998-08-07	2004-09-24	Pont Pharmaceuticals Du	Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
WO2000038618A2 (en) *	1998-12-24	2000-07-06	Du Pont Pharmaceuticals Company	SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US7160880B1 (en)	1999-05-14	2007-01-09	Cenes Limited	Short-acting benzodiazepines
CA2370141A1 (en)	1999-05-26	2000-12-07	James D. Rodgers	1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
US6960576B2 (en) *	1999-09-13	2005-11-01	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en)	1999-09-13	2003-01-07	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (en)	1999-10-08	2002-07-17	Bristol-Myers Squibb Pharma Company	AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
CA2395862A1 (en)	2000-02-17	2001-08-23	Hong Liu	Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
CN1436175A (zh)	2000-04-03	2003-08-13	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ－蛋白生产抑制剂的环状内酰胺
EP1268434A1 (en)	2000-04-03	2003-01-02	Bristol-Myers Squibb Pharma Company	Cyclic lactams as inhibitors of a-beta protein production
WO2001077086A1 (en)	2000-04-11	2001-10-18	Dupont Pharmaceuticals Company	SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US20100009966A1 (en) *	2001-04-11	2010-01-14	Bristol-Myers Squibb Pharma Company	Substituted lactams as inhibitors of abeta protein production
US6878363B2 (en) *	2000-05-17	2005-04-12	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CN1386118A (zh)	2000-06-01	2002-12-18	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
US20090062256A1 (en) *	2001-06-01	2009-03-05	Bristol-Myers Squibb Pharma Company	LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US6713470B2 (en) *	2002-01-22	2004-03-30	Ml Laboratories Plc	Method of treatment
US20040167146A1 (en) *	2002-01-22	2004-08-26	Karen Jackson	Method of treatment
US20030139396A1 (en) *	2002-01-22	2003-07-24	Karen Gibson	Method of treatment
US20040043990A1 (en) *	2002-04-09	2004-03-04	Karen Jackson	Method of treatment
KR101155335B1 (ko) *	2005-01-07	2012-06-11	엘지전자 주식회사	이동통신 단말기의 멀티미디어 메시지 동작방법
BRPI0714886B8 (pt)	2006-07-10	2021-05-25	Paion Uk Ltd	sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
JP2010526825A (ja) *	2007-05-10	2010-08-05	エーエムアールテクノロジーインコーポレイテッド	アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en)	2010-12-02	2012-06-07	Constellation Pharmaceuticals	Bromodomain inhibitors and uses thereof
US9422292B2 (en)	2011-05-04	2016-08-23	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2012174487A2 (en)	2011-06-17	2012-12-20	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
TWI602820B (zh)	2012-06-06	2017-10-21	星宿藥物公司	溴域抑制劑及其用途
US9624244B2 (en)	2012-06-06	2017-04-18	Constellation Pharmaceuticals, Inc.	Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
WO2015077572A1 (en)	2013-11-22	2015-05-28	CL BioSciences LLC	Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
PL3157928T3 (pl)	2014-06-20	2019-07-31	Constellation Pharmaceuticals, Inc.	Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ212436A (en) *	1984-06-25	1989-04-26	Rotta Research Lab	D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
US5004741A (en) *	1984-06-26	1991-04-02	Merck & Co., Inc.	Methods of antagonizing CCK or gastrin with benzodiazepine analogs
CA1332410C (en) *	1984-06-26	1994-10-11	Roger M. Freidinger	Benzodiazepine analogs
US4820834A (en) *	1984-06-26	1989-04-11	Merck & Co., Inc.	Benzodiazepine analogs
IT1215169B (it) *	1985-12-17	1990-01-31	Rotta Research Lab	Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
IT1217123B (it) *	1987-02-05	1990-03-14	Rotta Research Lab	Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
DK0411668T4 (da) *	1989-08-04	1999-08-09	Merck Sharp & Dohme	Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
US5153191A (en) *	1991-08-20	1992-10-06	Warner-Lambert Company	Cholecystokinin antagonists useful for treating depression

1990
- 1990-08-03 DK DK90114993T patent/DK0411668T4/da active
- 1990-08-03 JP JP2205335A patent/JPH0374328A/ja active Pending
- 1990-08-03 DE DE69017302T patent/DE69017302T3/de not_active Expired - Fee Related
- 1990-08-03 EP EP94106046A patent/EP0727215A3/en not_active Withdrawn
- 1990-08-03 AT AT90114993T patent/ATE119040T1/de not_active IP Right Cessation
- 1990-08-03 EP EP90114993A patent/EP0411668B2/en not_active Expired - Lifetime
1995
- 1995-01-30 US US08/380,467 patent/US5550126A/en not_active Expired - Fee Related
1996
- 1996-02-05 LV LVP-96-32A patent/LV11431B/en unknown
1997
- 1997-01-16 HK HK8197A patent/HK8197A/en not_active IP Right Cessation
- 1997-09-05 CY CY198397A patent/CY1983A/xx unknown

Also Published As

Publication number	Publication date
DE69017302T3 (de)	1999-08-05
DE69017302D1 (de)	1995-04-06
US5550126A (en)	1996-08-27
HK8197A (en)	1997-01-24
EP0727215A3 (en)	1996-11-06
ATE119040T1 (de)	1995-03-15
CY1983A (en)	1997-09-05
DE69017302T2 (de)	1995-09-28
LV11431A (lv)	1996-08-20
EP0727215A2 (en)	1996-08-21
DK0411668T3 (da)	1995-03-27
EP0411668A3 (en)	1992-01-29
LV11431B (en)	1996-12-20
JPH0374328A (ja)	1991-03-28
EP0411668B2 (en)	1998-11-11
EP0411668A2 (en)	1991-02-06
EP0411668B1 (en)	1995-03-01

Publication	Publication Date	Title
DK0411668T4 (da)	1999-08-09	Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
ATE398618T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
ATE101517T1 (de)	1994-03-15	Pharmazeutische zusammensetzung, enthaltend loratadin, ibuprofen und pseudoephedrin.
DK0751129T6 (da)	2020-05-25	Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
FR13C0062I2 (fr)	2015-11-20	Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
ATE348829T1 (de)	2007-01-15	Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
MX9700223A (es)	1997-04-30	Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
AR029190A1 (es)	2003-06-18	Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco
MX9200361A (es)	1992-07-01	Nuevo uso del antagonista de adenosina.
DE69113379D1 (de)	1995-11-02	3-Aryl-4(3H)chinazolinone als CCK Antagonisten und diese enthaltende pharmazeutische Zusammensetzungen.
ES2147616T3 (es)	2000-09-16	Derivados de piperidina con actividad antagonista del paf.
DE69321519D1 (de)	1998-11-19	Pharmazeutische Anthocyanoside enthaltende Zusammensetzungen zur oralen Anwendung
ATE205480T1 (de)	2001-09-15	2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
DK0636027T3 (da)	2000-01-31	Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
DE69830450D1 (de)	2005-07-14	Neue Atropisomere von 2,3-Disubstituierten-(5,6)-heteroarylkondensierten-pyrimidin-4-onen
DK598288A (da)	1989-04-28	Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
ATE141796T1 (de)	1996-09-15	2',5'-oligoadenylat-derivate zur verwendung als heilmittel
NO990450L (no)	1999-01-29	Behandling av sinnslidelser
EA200200656A1 (ru)	2002-12-26	НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
DE3879837D1 (de)	1993-05-06	Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ITMI911845A1 (it)	1993-01-04	Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
IT1246705B (it)	1994-11-26	Procedimento per l'eliminazione delle polveri nei filtri
MY103584A (en)	1993-08-28	8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2703921B1 (fr)	1995-07-21	Roulette double plateau equipee du dispositif d'alignement des chiffres des deux couronnes de numerotation.
DE68910021D1 (de)	1993-11-25	Oxaminsäureverbindungen und pharmazeutische Zusammensetzungen zur Anwendung bei der Verbesserung geschädigter Hirnfunktionen.